THIRD AMENDMENT TO AMENDED AND RESTATED SUTROVAX AGREEMENTSutrovax Agreement • November 13th, 2023 • Sutro Biopharma, Inc. • Biological products, (no disgnostic substances)
This Third Amendment (“Amendment No. 3”) to the Amended and Restated SutroVax Agreement, dated as of October 12, 2015, as amended on May 9, 2018 and May 29, 2018 (“Amended and Restated Agreement”), is made as of September 28, 2023 (“Amendment No. 3 Effective Date”) by and between Sutro Biopharma, Inc., having its principal place of business at 310 Utah Avenue, Suite 150, South San Francisco, CA 94080, USA (“Sutro”), and Vaxcyte, Inc., having its principal place of business at 825 Industrial Road, Suite 300, San Carlos, CA 94070 (“Vaxcyte”). Sutro and Vaxcyte are each referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED SUTROVAX AGREEMENTSutrovax Agreement • May 22nd, 2020 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • California
This Amended and Restated SutroVax Agreement (this “Agreement”), is made effective as of October 12, 2015 (the “Amendment Effective Date”), by and between Sutro Biopharma, Inc., having its principal place of business at 310 Utah Ave, Suite 150, South San Francisco, CA 94080 (“Sutro”), and SutroVax, Inc., having a principal place of business at 400 East Jamie Ct, Suite 205, South San Francisco CA 94080 (“SutroVax”), each a “Party” and collectively “Parties”, and amends and restates in its entirety that certain SutroVax Agreement, dated August 1, 2014 (the “Effective Date”), by and between Sutro and SutroVax (the “Original Agreement”).
